ANI Pharmaceuticals, Inc. (ANIP)

ANI Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	217.8	144.86	221.12	48.23	100.3	7.86
Short-Term Investments	5.72	6.31	-	-	-	-
Cash & Short-Term Investments	223.52	151.17	221.12	48.23	100.3	7.86
Cash Growth	-9.53%	-31.64%	358.49%	-51.92%	1175.43%	-87.38%
Receivables	225.65	221.73	162.08	165.44	128.53	95.79
Inventory	138.32	136.78	111.2	105.36	81.69	60.8
Prepaid Expenses	14.81	17.78	17.4	8.39	7.59	5.86
Restricted Cash	0.04	0.03	-	5.01	-	-
Other Current Assets	0.3	0.2	8.02	11.85	3.67	-
Total Current Assets	602.63	527.68	519.82	344.26	321.78	170.32
Property, Plant & Equipment	59.25	56.86	44.59	43.25	52.67	41.27
Long-Term Investments	-	4.9	6.24	8.8	-	-
Goodwill	60.53	59.99	28.22	28.22	27.89	3.58
Other Intangible Assets	520.32	541.83	209.01	251.64	294.12	188.51
Long-Term Deferred Tax Assets	92.03	85.11	90.71	81.36	67.94	51.7
Long-Term Deferred Charges	0.7	0.9	-	-	-	-
Other Long-Term Assets	7.55	6.42	5.84	2.56	7.21	5.81
Total Assets	1,343	1,284	904.42	760.09	771.6	461.19
Accounts Payable	54.57	45.66	36.68	29.31	22.97	11.26
Accrued Expenses	116.59	90.76	57.84	35.89	27.89	22.92
Current Portion of Long-Term Debt	13.22	9.17	0.85	0.85	0.85	13.24
Current Portion of Leases	-	2.04	-	-	-	-
Current Income Taxes Payable	3.29	6.75	8.16	-	-	3.91
Current Unearned Revenue	-	-	-	-	-	0.08
Other Current Liabilities	49.17	39.3	41.94	33.4	35.83	27.16
Total Current Liabilities	236.84	193.68	145.48	99.44	87.54	78.57
Long-Term Debt	608.35	614.92	284.82	285.67	286.52	186.55
Long-Term Leases	6.7	4.55	-	1.38	-	-
Other Long-Term Liabilities	29.52	42.02	16.53	35.06	38.8	0.37
Total Liabilities	881.39	855.17	446.82	421.55	412.86	265.49
Common Stock	0	0	0	0	0	0
Additional Paid-In Capital	541.9	519.65	514.1	403.9	387.84	214.35
Retained Earnings	-76.86	-100.28	-80.13	-97.29	-47.77	-4.97
Treasury Stock	-31.59	-21.04	-10.08	-5.09	-3.14	-2.25
Comprehensive Income & Other	3.31	5.34	8.86	12.17	-3.06	-11.44
Total Common Equity	436.76	403.68	432.75	313.69	333.89	195.7
Shareholders' Equity	461.61	428.53	457.6	338.54	358.74	195.7
Total Liabilities & Equity	1,343	1,284	904.42	760.09	771.6	461.19
Total Debt	628.26	630.68	285.67	287.9	287.37	199.8
Net Cash (Debt)	-404.74	-479.51	-64.55	-239.67	-187.07	-191.93
Net Cash Per Share	-20.68	-24.82	-3.55	-14.74	-14.85	-16.04
Filing Date Shares Outstanding	20.09	20.31	19.72	16.35	16.55	12
Total Common Shares Outstanding	20.13	19.65	19.12	16.35	16.12	12
Working Capital	365.8	334	374.34	244.82	234.24	91.76
Book Value Per Share	21.70	20.54	22.64	19.18	20.71	16.31
Tangible Book Value	-144.1	-198.14	195.52	33.83	11.88	3.61
Tangible Book Value Per Share	-7.16	-10.08	10.23	2.07	0.74	0.30
Land	-	1.58	1.55	1.55	5.95	4.67
Buildings	-	24.44	17.88	16.66	19.97	11.63
Machinery	-	68.7	50.41	53.15	46.77	39.11
Construction In Progress	-	4.57	7.69	4.6	2.94	3.39
Leasehold Improvements	-	1.3	-	-	-	-

Updated Aug 8, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q